• Press Office

    Posted in category ABPI statement by Press Office on 03/04/2014

    ABPI statement in response to the 'Pharmaceutical Price Regulation Scheme Twelfth Report to Parliament'

Commenting on the ‘Pharmaceutical Price Regulation Scheme Twelfth Report to Parliament’, ABPI Chief Executive Stephen Whitehead said:


​ "This report rightly acknowledges the significant contribution the pharmaceutical industry makes to the UK economy and population as a whole. The pharmaceutical sector in the UK has 477 companies employing over 70,000 people and generates a turnover of £29 billion. The report also recognises the high level of pharmaceutical investment in research and development in the UK - £11.5 million each day. 

“It is disappointing that, unlike previous reports to Parliament and as per the terms of both 2009 and 2014 PPRS agreements, this report does not include international price comparisons of branded innovative medicines in the UK with other countries. Previous comparisons have consistently shown that the price of branded medicines in the UK is among the lowest compared to other European and global comparator countries. Recent research also shows that total medicine costs in the UK represent only 0.9% of GDP¹ which compares to 1.2% average across countries including the USA, France, Spain, Germany and Ireland².

“One hundred and thirty four companies, representing 93% of the UK, branded industry joined the new voluntary PPRS, following the most complex pricing negotiations ever. Whilst Government initiatives to help industry are valuable it is essential that this new agreement goes hand-in-hand with action by the Government and the NHS to ensure patients have access to the best medicines.”



Notes to editors

 ¹OHE, UK NHS medicines bill projection 2012 – 2015, analysis for the ABPI, June 2012.

²IMS Health, World Review Analyst 2013, OECD Health Database. All data accessed December 2013.  

The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.  

Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.  

The ABPI is recognised by Government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.  

Media enquiries

ABPI Press Office

Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811
Email: pressoffice@abpi.org.uk

Print this page icon Print this page
Please choose the subject of your enquiry from the list below:
Code to enter for submitting the form
Enter the above code here:
Can't read? Try different words.